Cover Image
市場調查報告書

全球ADHD(注意缺陷多動障礙(簡稱過動症))治療藥市場

Global ADHD Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317268
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
全球ADHD(注意缺陷多動障礙(簡稱過動症))治療藥市場 Global ADHD Drugs Market 2014-2018
出版日期: 2014年10月22日 內容資訊: 英文 80 Pages
簡介

全球ADHD(注意缺陷多動障礙(簡稱過動症))治療藥市場,預計2013年∼2018年期間,年複合成長率為5.33%。

本報告提供全球ADHD(注意缺陷多動障礙(簡稱過動症))治療藥市場相關調查分析、市場規模與成長率、市場趨勢、推動市場要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Strattera
  • Concerta/Ritalin
  • Focalin
  • Intuniv
  • Vyvanse/Elvanse/Venvanse

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:各產品類型

  • 刺激藥
  • 非刺激藥

第9章 市場區隔:各給藥途徑

  • 口服
  • 經皮

第10章 市場區隔:各劑型

  • 固態劑
  • 液劑

第11章 地區區分

  • 全球ADHD治療藥市場:地區區分
  • 南北美的ADHD治療藥市場
    • 市場概要
    • 市場規模與預測
    • 美國的ADHD治療藥市場
  • EMEA的ADHD治療藥市場
    • 市場概要
    • 市場規模與預測
    • 西班牙的ADHD治療藥市場
  • 亞太地區ADHD治療藥市場
    • 市場概要
    • 市場規模與預測
    • 日本的ADHD治療藥市場

第12章 主要國家

第13章 罹患率和盛行率

第14章 購買標準

第15章 市場成長因素

第16章 成長因素與其影響

第17章 市場課題

第18章 成長因素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 業者情勢

  • 競爭情形
    • 主要消息
    • M & A
  • 市場佔有率分析
    • Eli Lilly
    • Janssen
    • Novartis
    • Shire
  • 其他卓越供應商

第22章 產品研發線

第23章 主要供應商分析

  • Eli Lilly and Co.
    • 主要資料
    • 產業概要
    • 產業區分:各收益
    • 產業區分:各收益
    • 各銷售地區
    • 產業策略
    • 主要的發展
    • SWOT分析
  • Janssen Pharmaceuticals
  • Novartis
  • Shire

第24章 相關報告

圖表清單

目錄
Product Code: IRTNTR4390

About ADHD

ADHD is a psychiatric disorder, which is mostly found in children. However, adults have also been reported to be diagnosed with ADHD. The patients with ADHD suffer from several problems including hyperactivity, impulsiveness, and lack of focus and concentration. The causes of ADHD are not known. It is believed to be linked with genetic and environmental causes. However, it has been reported to be related with the decrease in the extraneuronal levels of norepinephrine and dopamine. In addition, the patients have an abnormality in the brain structure. It is more prevalent in boys than girls. The management of ADHD is done by counseling, medications, and lifestyle changes.

TechNavio's analysts forecast the Global ADHD Drugs market to grow at a CAGR of 5.33 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global ADHD Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of ADHD, which include:

  • Stimulants
  • Non-stimulants

TechNavio's report, the Global ADHD Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ADHD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Eli Lilly and
  • Janssen
  • Novartis
  • Shire

Other Prominent Vendors

  • Actavis
  • Alcobra
  • Amarantus
  • Boehringer Ingelheim
  • Concordia
  • Curemark
  • GlaxoSmithKline
  • Hisamitsu
  • Impax
  • Intellipharmaceutics
  • Mylan
  • Neurovance
  • Noven
  • Par Pharmaceuticals
  • Sanofi
  • Shionogi
  • Sunovion
  • Teva
  • Tris Pharma

Market Driver

  • Presence of Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • Unknown Etiology
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

  • 04.1. Strattera
  • 04.2. Concerta/Ritalin
  • 04.3. Focalin
  • 04.4. Intuniv
  • 04.5. Vyvanse/Elvanse/ Venvanse

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Product Type

  • 08.1. Stimulants
  • 08.2. Non-stimulants

09. Market Segmentation by Route of Administration

  • 09.1. Oral
  • 09.2. Transdermal

10. Market Segmentation by Dosage Form

  • 10.1. Solid
  • 10.2. Liquid

11. Geographical Segmentation

  • 11.1. Global ADHD Drugs Market by Geographical Segmentation 2013-2018
  • 11.2. ADHD Drugs Market in Americas
    • 11.2.1. Market Overview
    • 11.2.2. Market Size and Forecast
    • 11.2.3. ADHD Drugs Market in the US
  • 11.3. ADHD Drugs Market in EMEA
    • 11.3.1. Market Overview
    • 11.3.2. Market Size and Forecast
    • 11.3.3. ADHD Drugs Market in Spain
  • 11.4. ADHD Drugs Market in APAC
    • 11.4.1. Market Overview
    • 11.4.2. Market Size and Forecast
    • 11.4.3. ADHD Drugs Market in Japan

12. Key Leading Countries

13. Rate of Incidence and Prevalence

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2013
    • 21.2.1. Eli Lilly
    • 21.2.2. Janssen
    • 21.2.3. Novartis
    • 21.2.4. Shire
  • 21.3. Other Prominent Vendors

22. Pipeline Portfolio

23. Key Vendor Analysis

  • 23.1. Eli Lilly and Co.
    • 23.1.1. Key Facts
    • 23.1.2. Business Overview
    • 23.1.3. Business Segmentation by Revenue 2013
    • 23.1.4. Business Segmentation by Revenue 2012 and 2013
    • 23.1.5. Sales by Geography
    • 23.1.6. Business Strategy
    • 23.1.7. Key Developments
    • 23.1.8. SWOT Analysis
  • 23.2. Janssen Pharmaceuticals
    • 23.2.1. Key Facts
    • 23.2.2. Business Overview
    • 23.2.3. Product Segmentation
    • 23.2.4. Business Strategy
    • 23.2.5. Recent Developments
    • 23.2.6. SWOT Analysis
  • 23.3. Novartis
    • 23.3.1. Key Facts
    • 23.3.2. Business Overview
    • 23.3.3. Business Segmentation by Revenue 2013
    • 23.3.4. Business Segmentation by Revenue 2012 and 2013
    • 23.3.5. Sales by Geography
    • 23.3.6. Business Strategy
    • 23.3.7. Key Developments
    • 23.3.8. SWOT Analysis
  • 23.4. Shire
    • 23.4.1. Key Facts
    • 23.4.2. Business Overview
    • 23.4.3. Geographical Segmentation by Revenue 2013
    • 23.4.4. Business Strategy
    • 23.4.5. Recent Developments
    • 23.4.6. SWOT Analysis

24. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global ADHD Drugs Market 2013-2018 (US$ billion)
  • Exhibit 3: Global ADHD Drugs Market by Product Type
  • Exhibit 4: Global ADHD Drugs Market Segmentation by Product Type 2013
  • Exhibit 5: Global ADHD Drugs Market by Route of Administration
  • Exhibit 6: Global ADHD Drugs Market Segmentation by Route of Administration 2013
  • Exhibit 7: Global ADHD Drugs Market by Dosage Form
  • Exhibit 8: Global ADHD Drugs Market Segmentation by Dosage Form 2013
  • Exhibit 9: Global ADHD Drugs Market by Geographical Segmentation 2013
  • Exhibit 10: ADHD Drugs Market in Americas 2013-2018 (US$ million)
  • Exhibit 11: ADHD Drugs Market in the US 2013-2018 (US$ million)
  • Exhibit 12: ADHD Drugs Market in EMEA 2013-2018 (US$ million)
  • Exhibit 13: ADHD Drugs Market in Spain 2013-2018 (US$ million)
  • Exhibit 14: ADHD Drugs Market in APAC 2013-2018 (US$ million)
  • Exhibit 15: ADHD Drugs Market in Japan 2013-2018 (US$ million)
  • Exhibit 16: Global ADHD Drugs Market Share Analysis 2013
  • Exhibit 17: Region-wise Sales Comparison of Strattera 2010-2013 (US$ million)
  • Exhibit 18: YOY Sales Comparison of Strattera 2010-2013 (US$ million)
  • Exhibit 19: YOY Sales Comparison of Strattera in the US 2010-2013 (US$ million)
  • Exhibit 20: YOY Sales Comparison of Strattera in ROW 2010-2013 (US$ million)
  • Exhibit 21: YOY Sales Comparison of Concerta 2007-2013 (US$ million)
  • Exhibit 22: Region-wise Sales Comparison of Novartis' Focalin and Ritalin 2010-2013 (US$ million)
  • Exhibit 23: YOY Sales Comparison of Novartis' Focalin and Ritalin 2008-2013 (US$ million)
  • Exhibit 24: YOY Sales Comparison of Novartis' Focalin and Ritalin in the US 2010-2013 (US$ million)
  • Exhibit 25: YOY Sales Comparison of Novartis' Focalin and Ritalin in ROW 2010-2013 (US$ million)
  • Exhibit 26: Sales Comparison of Shire's ADHD Drugs 2009-2013 (US$ million)
  • Exhibit 27: YOY Sales Comparison of Vyvanse 2008-2013 (US$ million)
  • Exhibit 28: YOY Sales Comparison of Intuniv 2009-2013 (US$ million)
  • Exhibit 29: YOY Sales Comparison of Adderall 2008-2013 (US$ million)
  • Exhibit 30: Late Stage Pipeline Molecules for the Treatment of ADHD
  • Exhibit 31: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 32: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 33: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 34: Janssen Pharmaceuticals: Product Segmentation 2013
  • Exhibit 35: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 36: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 37: Novartis AG: Sales by Geography 2013
  • Exhibit 38: Shire: Geographical Segmentation by Revenue 2013
Back to Top